Boston Scientific’s Parashar Patel
This article was originally published in The Gray Sheet
Executive Summary
Former Deputy Director of CMS' Hospital & Ambulatory Policy Group joins Boston Scientific as VP-reimbursement and outcomes planning May 14. Elizabeth Richter recently became CMS HAPG's new director (1"The Gray Sheet" May 12, 2003, p.9)...
You may also be interested in...
AdvaMed Medicare Policy Meeting In Brief
New tech add-on application status: Medtronic InFuse bone graft/LT-Cage lumbar tapered fusion system's acceptance for add-on payment under the hospital inpatient prospective payment system will depend on the content of "data [gathered] between the proposed rule and final, to assess whether it meets the payment adequacy test," Stephen Philips, CMS division of acute care deputy director, reported at the AdvaMed seminar on Medicare policy in Baltimore May 8. The firm was denied a new tech add-on payment last year due to insufficient data (1"The Gray Sheet" July 6, 2002, p. 9). The inpatient proposed rule is slated for May 21 release....Guilford Gliadel wafer: New tech add-on payment likely will be denied for use in patients undergoing surgery for newly diagnosed malignant glioma, an indication approved in February, because the product was originally approved in 1996. Therefore, receiving a new ICD-9 code "does not start the clock ticking anew as far as [being classified as a] new technology," CMS' Philips explained May 8...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.